



To: Board Members

Subject: Executive Officer Report

a. CURES Statistics FY 2024-25

Relevant Law: [Health and Safety Code section 11165](#) establishes the Controlled Substance Utilization Review and Evaluation System (CURES) maintained by the State of California Department of Justice (DOJ) for electronic monitoring of, and internet access to information regarding, the prescribing and dispensing of schedule II-V controlled substances. Subdivision (h)(1) establishes provisions for the department to enter into an agreement with an entity operating an interstate data sharing hub, or an agency operating a prescription drug monitoring program in another state, for purposes of interstate data sharing of prescription drug monitoring program information.

The Department of Justice released CURES data for FY 2024-25. The data reveals that as of June 2025, there are 276,396 registered users. As previously shared, currently two-way interstate data sharing is limited to Oregon. Data reveals that 153,079 outbound requests were performed. Data for inbound inquiries is higher in part because the U.S. Department of Veterans Affairs has the ability to query the CURES system. (Note: as previously reported, California practitioners cannot query the VA's records.) The data¹ also reveals the following dispensing data:

- 15.6 million schedule II controlled substance prescriptions
- 3 million schedule III controlled substances prescriptions
- 12.5 million schedule IV controlled substance prescriptions
- 1.9 million schedule V controlled substance prescriptions

b. Medication Error Reporting

Relevant Law: Business and Professions Code (BPC) section 4113.1 establishes requirements for a community pharmacy to report, either directly or through a designated third party, medication errors to an entity approved by the Board.

Background: Following the state contracting process, as part of the Board's September 12, 2024 meeting, the Board approved the Institute for Safe Medication Practices (ISMP) as the entity to receive and review medication error reports under BPC section 4113.1. The contract was signed and approved on January 30, 2025.

¹ Numbers have been rounded. Actual numbers are included in Attachment 1.

As reported in April 2025, staff have been working with ISMP on implementation activities. In April, the Board and ISMP released information about how to register with ISMP. More recently, the Board released a fact sheet that included information about the California Medication Error Reporting (CAMER) data elements and updated the dedicated [webpage](#) on the Board's website to include this information. In the fact sheet, the Board advised licensees that medication errors that occur on or after September 1, 2025, must be reported to the CAMER system consistent with legal requirements established.

Recent Update:

As of October 20, 2025, a total of 3,213 medication error reports were submitted to CAMER. Medication error reports were received from the following:

- 2,014: community chain pharmacies
- 554: non-chain community pharmacies
- 314: mail order pharmacies
- 170: closed-door pharmacies
- 99: specialty pharmacies
- 62: hospital outpatient pharmacies

The Board anticipates receiving the first semi-annual report from ISMP in January 2026 based on medication error reports submitted to CAMER September – December 2025.

c. National Association of Boards of Pharmacy (NABP) District 8 Meeting

On October 6-7, 2025, President Oh and Executive Officer Sodergren attended the NABP District 8 Meeting. In addition to educational sessions, the District Meeting provided an opportunity for colleagues from sister boards to discuss emerging issues and collaborate with educators on issues including declining enrollment, potential workforce shortages, and new accreditation standards. During the meeting, elections were held for the officer positions for the District. Executive Officer Sodergren was elected as the Chairperson and President Oh was reelected as Treasurer.

In addition, EO Sodergren will represent the District on the Committee on Resolutions during the NABP annual meeting scheduled next year.

d. Prescriptions and Patients, Addressing Challenges, Finding Opportunities, A Joint Forum on Controlled Substances and Medications for Opioid Use Disorder Access

As previously announced, the California State Board of Pharmacy, along with the Medical Board of California, Osteopathic Medical Board, Board of Registered Nursing, and others are hosting a joint forum to help facilitate better collaboration and understanding specifically related to access to controlled substances. The forum is scheduled for December 17, 2025, and will be convened both in person and via WebEx.

It is anticipated that the joint forum will include presentations from a variety of agencies, panel discussion, and breakout sessions. The focus of the breakout sessions will be to discuss opportunities for health care providers to collaborate to advance patient care.

As details are finalized additional information will be released and posted on the dedicated [webpage](#).

e. Joint Listening Session with California Veterinary Medical Board (CVMB)

On October 1, 2025, the Board convened a joint listening session with the CVMB. President Oh and Member Serpa, as Chairperson of the Board's Enforcement and Compounding Committee, represented the Board.

The listening session provided a forum for stakeholders and respective board representatives to discuss the compounding of preparations for animal patients. The session provided an opportunity for information sharing as well as clarification on compounding requirements. The session also highlighted the opportunity to provide some additional education.

Board staff will be working with staff at CVMB to develop educational materials including resources to verify licensure of outsourcing facilities and locate where product lists are maintained and published by the Federal Food and Drug Administration, as well as some operational reminders.

f. Proposition 34, Protect Patients Now Act of 2024

The Protect Patients Now Act of 2024 (Act) was a ballot initiative approved by voters in 2024. The Act added provisions to the Welfare and Institutions Code (see sections [14124.39-14124.52](#)). Among its provisions, the Act establishes requirements for a "Prescription Drug Price Manipulator" (as defined in subdivision (l) of WIC section 14124.48) to report specified information to certain agencies, including the Board, by no later than December 31, 2025.

The Board is working on several implementation activities including establishing a dedicated email for purposes of public comment and a dedicated webpage. It is anticipated these will be go live by mid-November.

The Board is collaborating with several other state agencies on implementation activities also charged with enforcing by the Act.

g. Regulations Report

The Board has several regulations in various stages of promulgation. Provided below is the status of the pending regulations; however, staff note that with the passage of Assembly Bill 1503 (Berman, Chapter 196, Statutes of 2025) several changes are no longer needed. Note: Regulations being considered by the Board during the meeting are not included below.

1. Title 16, California Code of Regulations Section 1746.6, Medication Assisted Treatment Protocol

Approved by the Board: February 7, 2023

Current Status: Board staff are preparing the documents to withdraw the proposed regulations following the enactment of AB 1503.

2. **Title 16, California Code of Regulations Section 1707.4, Central Fill Pharmacies**
Approved by the Board: August 1, 2024
Current Status: Open comment period from October 17, 2025, to December 1, 2025.
3. **Title 16, California Code of Regulations Section 1715.1, Automated Drug Delivery Systems (ADDs) Self-Assessment**
Approved by the Board: April 25, 2024
Current Status: Board staff will assess whether the regulation is warranted with the enactment of AB 1503.
4. **Title 16, California Code of Regulations Sections 1750 and 1750.1, Outsourcing Facilities**
Approved by the Board: October 26, 2022
Current Status: Board staff will be preparing the documents to move forward with Section 1750 as Section 1750.1 is not required with the enactment of AB 1503.
5. **Title 16, California Code of Regulations Section 1713, Automated Patient Delivery Systems (APDS) Consultation**
Approved by the Board: April 24, 2024
Current Status: Submitted to DCA for post-adoption final review on August 4, 2025.
6. **Title 16, California Code of Regulations Section 1707.51, Accessible Prescription Drug Labels**
Approved by the Board: June 20, 2025
Current Status: Submitted to DCA for pre-review on October 14, 2025.



FY 2024-2025 Statistics

Registered Users		
		2024/2025
By Month		
	Jul-24	265,805
	Aug-24	266,738
	Sep-24	268,211
	Oct-24	269,539
	Nov-24	270,409
	Dec-24	271,185
	Jan-25	272,042
	Feb-25	272,981
	Mar-25	274,003
	Apr-25	274,906
	May-25	275,502
	Jun-25	276,396
Total New Users		4,354
Note:		
Stats are from the 1st of the month to the last day of the month		
Reports for the month are generated on the 1st of the following month		



FY 2024-2025 Statistics

Number of Search Counts				
2024/2025				
		App PAR Searches	IEWS PAR Searches	Total
By Month				
	Jul-24	2,475,899	14,015,782	16,491,681
	Aug-24	2,437,905	14,367,627	16,805,532
	Sep-24	2,317,602	13,585,144	15,902,746
	Oct-24	2,536,250	14,535,197	17,071,447
	Nov-24	2,252,347	12,603,673	14,856,020
	Dec-24	2,372,792	13,684,784	16,057,576
	Jan-25	2,478,235	14,740,226	17,218,461
	Feb-25	2,273,846	12,644,303	14,918,149
	Mar-25	2,483,044	13,602,302	16,085,346
	Apr-25	2,514,172	13,629,648	16,143,820
	May-25	2,424,502	13,264,631	15,689,133
	Jun-25	2,440,507	12,657,140	15,097,647
Total Search Counts		29,007,101	163,330,457	192,337,558

Note:

Stats are from the 1st of the month to the last day of the month

Reports for the month are generated on the 1st of the following month



FY 2024-2025 Statistics

Number of CURES Outbound Interstate Searches				
2024/2025				
By Month		Web App	IEWS	Total
	Jul-24	13,342	3	13,345
	Aug-24	13,576	1	13,577
	Sep-24	12,133	2	12,135
	Oct-24	14,433	1	14,434
	Nov-24	12,019	11	12,030
	Dec-24	12,672	3	12,675
	Jan-25	14,250	4	14,254
	Feb-25	11,529	6	11,535
	Mar-25	11,878	2	11,880
	Apr-25	12,296	4	12,300
	May-25	12,853	8	12,861
	Jun-25	12,047	6	12,053
Totals		153,028	51	153,079
Note:				
Stats are from the 1st of the month to the last day of the month				
Reports for the month are generated on the 1st of the following month				



FY 2024-2025 Statistics

Number of Inbound Interstate Searches

2024/2025

By Month		OR	VHA	Total
	Jul-24	0	0	0
	Aug-24	0	0	0
	Sep-24	0	0	0
	Oct-24	0	0	0
	Nov-24	0	0	0
	Dec-24	0	0	0
	Jan-25	202	0	202
	Feb-25	160	0	160
	Mar-25	208	0	208
	Apr-25	201	0	201
	May-25	209	11,232	11,441
	Jun-25	142	363,769	363,911
Totals		1,122	375,001	376,123

Note:

Stats are from the 1st of the month to the last day of the month

Reports for the month are generated on the 1st of the following month



FY 2024-2025 Statistics

Number of CURES Help Desk Requests			
2024/2025			
By Month		Phone	Email
	Jul-24	2,783	692
	Aug-24	2,553	685
	Sep-24	2,112	521
	Oct-24	2,672	725
	Nov-24	1,807	513
	Dec-24	1,686	541
	Jan-25	1,978	721
	Feb-25	1,570	484
	Mar-25	1,815	571
	Apr-25	2,233	715
	May-25	2,133	641
	Jun-25	1,997	573
Totals		25,339	7,382

Note:

Stats are from the 1st of the month to the last day of the month

Reports for the month are generated on the 1st of the following month



FY 2024-2025 Statistics

2024/2025	
Number of Distinct Prescriptions	33,957,698
Number of Prescriptions Filled by Schedule	
Schedule II	15,610,100
Schedule III	3,005,938
Schedule IV	12,506,511
Schedule V	1,952,590
R	13
Over-the-counter product	910,156
Total	33,985,308

Note:

Reports for the month are generated on the 1st of the following month

1. Each component of a compound is submitted as a separate prescription record. The number of distinct prescriptions rolls compound prescriptions into a single count.
2. The number of distinct prescriptions and the number of prescriptions filled by schedule will not be equal because a compound can consist of multiple drugs with varying schedules.
3. R = Not classified under the Controlled Substances Act; includes all other prescription drugs